<?xml version="1.0" encoding="UTF-8"?>
<ref id="B34-pharmaceutics-12-00388">
 <label>34.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cosma</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>BÃ¼hler</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Nagaraj</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Staib</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Hammarin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Wahren</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Goebel</surname>
    <given-names>F.D.</given-names>
   </name>
   <name>
    <surname>Erfle</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Sutter</surname>
    <given-names>G.</given-names>
   </name>
  </person-group>
  <article-title>Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus</article-title>
  <source>Clin. Diagn. Lab. Immunol.</source>
  <year>2004</year>
  <volume>11</volume>
  <fpage>406</fpage>
  <lpage>410</lpage>
  <pub-id pub-id-type="doi">10.1128/CDLI.11.2.406-410.2004</pub-id>
  <pub-id pub-id-type="pmid">15013995</pub-id>
 </element-citation>
</ref>
